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Purpose: The aim of this study was to define the clinical significance of transurethral resection of the prostate (TURP) in patients with 
benign prostate hyperplasia (BPH) and an elevated prostate-specific antigen (PSA) level.
Methods: We retrospectively evaluated patients with BPH, lower urinary tract symptoms (LUTS; International Prostate Symptom 
Score [IPSS]≥8), an elevated serum PSA level (≥4 ng/mL), and previous negative transrectal ultrasonography (TRUS) guided prostate 
biopsy. The PSA level after TURP was monitored by long-term follow-up. The tumor detection rate on resected prostate tissue, IPSS, 
maximal urinary flow rate (Qmax), and postvoid residual urine (PVR) were analyzed. 
Results: One-hundred and eighty-six patients were enrolled. Histological examination of resected tissue by TURP revealed prostate 
cancer in 12 of these patients (6.5%). Among 174 patients without prostate cancer, the mean PSA level and the PSA normalization rate 
in 112 patients followed up at postoperative day (POD) 3 months were 1.26±0.13 ng/mL and 94.6%, respectively. The mean PSA level 
and the PSA normalization rate were 1.28±1.01 ng/mL and 95.7% in 47 patients at 1st year, 1.17±0.82 ng/mL and 97.1% in 34 patients 
at second years, and 1.34±1.44 ng/mL and 97.2% in 36 patients at third years of TURP. One patient showed a dramatic increase in the 
PSA level was diagnosed with prostate cancer at 7 years after TURP. IPSS, quality of life, Qmax, and PVR were improved significantly at 
POD 3 months compared to baseline (P<0.05), respectively.
Conclusions: TURP significantly reduced the serum PSA level, which was maintained for at least 3 years. This could be helpful to 
screen the prostate cancer using PSA value in the patient with previous negative biopsy and elevated PSA. In addition, TURP improves 
IPSS, Qmax, and PVR in patients with BPH, moderate LUTS, and an elevated PSA level. 
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INTRODUCTION
The serum prostate-specific antigen (PSA) level allows for the 
early diagnosis and a chance for successful treatment of pros-
tate cancer. However, PSA is not a cancer-specific marker, and 
other factors can increase its level as well [1]. While patients 
with an elevated PSA level and a positive prostate biopsy are 
treated by radical prostatectomy, radiotherapy, or hormonal 
therapy, treatment methods are not defined for patients with 
an elevated or rising serum PSA level despite previous nega-
tive prostate biopsy. Although the % free-PSA, PSA density 
(PSAD), PSA velocity, and age-specific PSA are useful clinical 
parameters, they are not sufficient to prevent misdiagnosis 
[2]. In addition, the accuracy of the prostate biopsy diagnosis 
is enhanced by increasing the number of biopsy cores and 
changing the biopsy target zone [3]; however, although re-
peated and extended biopsies were negative, the anxiety by 
the elevated or rising PSA does not disappear. 
 Studies have shown an α-blocker and a 5-α reductase inhib-
itor (5-ARI) to improve lower urinary tract symptoms (LUTS) 
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al zone biopsies, were performed from 2008. Before TURP, a 
urodynamic study (UDS) was performed in selected patients, 
and the bladder outlet obstruction index (BOOI = detrusor 
pressures at peak flow–2 maximal urinary flow rate) was cal-
culated [10]. Under spinal or general anesthesia, TURP was 
performed with a mono- or bipolar loop resectoscope. The 
experienced pathologist histologically examined the resected 
prostate tissue. Three months after TURP, the serum PSA 
level, maximal urinary flow rate (Qmax), postvoid residual 
urine (PVR), and IPSS (International Prostate Symptom Score) 
were determined. The serum PSA level was measured at 3- or 
6-month intervals for 3 years. The ethics committee approved 
this study.
RESULTS
One-hundred and eighty-six patients were enrolled based 
on inclusion criteria. Table 1 lists the preoperative variables. 
Twelve patients (6.5%) were diagnosed with prostate cancer 
by TURP (one patients, Gleason score of 8; five patients, Glea-
son score of 7; five patients, Gleason score of 6; and one pa-
tient, Gleason score of 4). Except for 12 patients with prostate 
cancer, 174 patients were analyzed. The preoperative serum 
PSA level of the 12 patients with prostate cancer and the 174 
patients without cancer was 7.15 ±2.36 and 8.47 ±4.16 ng/
mL, respectively. The PSAD was 0.13 ±0.04 and 0.14 ±0.1, re-
spectively. There was no significant difference in the PSA and 
PSAD compared to patient with prostate cancer (Table 1). 
 The average serum PSA level was 1.26 ± 1.13 ng/mL in 112 
patients followed up at 3 months after TURP, 1.28 ± 1.01 ng/
mL in 47 patients at 1 year, 1.17 ± 0.82 ng/mL in 34 patients at 
2 years; and 1.34 ± 1.44 ng/mL in 36 patients at 3 years (Fig. 1). 
and to block the progression of BPH [4,5]. However, the 
α-blocker cannot reduce the PSA. Although the 5-ARI reduces 
the PSA, quantification of the PSA level may be inaccurate be-
cause the response of PSA to 5-ARI is heterogeneous [6,7]. In 
addition, the previous studies that concerned increasing of the 
high grade prostate cancer incidence after 5-ARI treatment [8] 
give another difficult issue to the doctor in the treatment of the 
BPH with the elevated or rising PSA. 
 The aim of this study was to define the clinical significance 
of transurethral resection of the prostate (TURP) in patients 
with BPH and an elevated PSA level in terms of PSA value, 
oncologic and functional outcomes. 
MATERIALS AND METHODS
Patients who came to the hospital for LUTS from March 2003 
to August 2010 were included in this study. Except for those 
who were previously treated by TURP, patients received 5-ARI, 
underwent transurethral instrumentation or catheterization, 
and showed acute urinary retention (AUR) within the past 6 
weeks. A prostate biopsy was performed when the serum PSA 
level was > 4 ng/mL. After exclusion of patients with prostate 
cancer in previous prostate biopsy, patients who had indica-
tions for TURP such as persistent (LUTS) despite medical 
treatment, recurrent acute AUR or bladder stone etc., were 
underwent surgery, and the medical records of these patients 
were examined retrospectively. 
 All prostate biopsy was performed by transrectal ultraso-
nography (TRUS) guided prostate biopsy. In this hospital, 
eight core biopsies, including two transitional zone and six 
standard core biopsies [9], were performed from 2003 to 2007. 
Fourteen core biopsies, including 12 cores and two transition-
Table 1. Preoperative clinical variables
Variable
All patients 
(n=186)
Patients without cancer
 (n=174)
Patients with cancer
(n=12)
Age (yr) 71.4±8.12 71.3±8.1 72.9±8.1
PSA (ng/mL) 8.48±4.1 8.69±4.62 7.15±2.36
Prostate volume (mL) 71.5±27.4 72.2±27.6 60.0±21.5
Transitional volume (mL) 43.7±37.2 44.3±38.1 34.5±18.2
PSAD 0.14±0.10 0.14±0.98 0.13±0.44
Resected weight (g) 27.7±17.6 27.5±17.5 30.2±18.7
BOOI 56.3±29.9 56.3±30.4 64.4±31.0
Qmax (mL/sec) 8.69±3.89 8.6±3.9 9.84±3.27
PVR (mL) 132.3±198.9 129.3±197.3 178.4±242.2
Total IPSS 20.1±8.1 20.1±8.0 19.3±10.0
QoL 4.3±1.27 4.28±1.19 3.4±2.0
Values are presented as mean±standard deviation.
PSA, prostate specific antigen; PSAD, PSA density; BOOI, bladder outlet obstruction index; Qmax, maximal urinary flow rate; PVR, postvoid residual 
urine; IPSS, international prostate symptom score; QoL, quality of life.
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28, and 31 patients continued to be followed for first, second, 
and third years after TURP, respectively. During three years 
follow-up, the serum PSA level increased by > 1 ng/mL in 
three patients. One of these three patients did not show PSA 
normalization and presented with atypical small acinar pro-
liferation after three consecutive prostate biopsies. Another 
patient was diagnosed with prostate cancer 7 years after 
TURP. During the initial visit, the patient had a serum PSA 
level of 15.7 ng/mL; however, it decreased to 1.69 ng/mL after 
TURP. Seven years after TURP, the PSA level increased again 
to 8.12 ng/mL, and the patient was diagnosed with prostate 
cancer by TRUS guided biopsy. Robot-assisted laparoscopic 
radical prostatectomy was performed, and the cancer was 
staged as T3cN0M0 with a Gleason score of 4+3.
 Of the 115 patients who received preoperative UDS, the pre-
operative PSA level and the PSAD of 80 patients with BOOI ≥ 40 
were 8.81 ± 4.48 and 0.13 ± 0.07 ng/mL, respectively. There 
were no significant differences between these values and 
those of 35 patients with BOOI < 40 (9.24 ± 5.90 and 0.1 ± 0.17 
ng/mL; P= 0.703 and P= 0.085). Seventy-nine patients who 
received preoperative UDS was measured postoperative PSA 
level at 3 months after TURP. Among these patients, the aver-
The PSA normalization rate at the third month, and first, sec-
ond, and third year after TURP was 94.6% (106/112), 95.7% 
(45/47), 97.1% (33/34), and 97.2% (35/36), respectively (Table 
2). Of the 112 patients followed up at 3 months after TURP, 40, 
Fig. 1. The serum prostate specific antigen (PSA) level at base-
line and postoperative months 3, 12, 24, and 36 after transure-
thral resection of prostate.
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Table 3. Characteristics in the patientsa) without prostate cancer according to the presence of urodynamic bladder outlet obstruction
Variable
Obstructive pattern 
(AG NO>40, n=55)
Nonobstructive pattern 
(AG NO≤40, n=24)
P-value
PSA (ng/mL) 9.37±5.00 9.38±5.96 0.996
Prostate volume (mL) 76.38±24.34 65.18±21.01 0.044
Transitional volume (mL) 42.69±19.32 53.94±85.7 0.531
PSAD 0.14±0.08 0.18±0.19 0.338
BOOI 67.5±31.3 26.4±10.9 <0.001
Resection weight (g) 31.3±17.3 23.7±12.5 0.034
RPWR 0.59±0.16 0.61±0.27 0.700
Qmax (mL/sec) 8.71±3.66 9.97±4.03 0.223
PVR (mL) 181.2±232.6 57.4±51.7 0.016
Total IPSS 20.2±7.9 18.7±8.4 0.521
QoL 4.42±1.20 3.95±1.32 0.185
Extent of the PSA decrement at 3 months after TURP (ng/mL) 8.09±4.96 8.09±5.85 0.997
Values are presented as mean±standard deviation.
AG NO, Abrams-Griffiths nomogram; PSA, prostate specific antigen; PSAD, PSA density; BOOI, bladder outlet obstruction index; RPWR, residual pros-
tatic weight ratio, calculated as the prostate weight after TURP divided by the initial weight; Qmax, maximal urinary flow rate; PVR, postvoid residual 
urine; IPSS, international prostate symptom score; QoL, quality of life; TURP, transurethral resection of prostate. 
a)Seventy-nine patients underwent urodynamic study among 112 patients who followed up at 3 months postoperatively.
Table 2. Mean PSA and PSA normalization rate after transurethral resection of prostate
Postoperative time (mo)
3 12 24 36
PSA normalization, n (%) 106/112 (94.6) 45/47 (95.7) 33/34 (97.1) 35/36 (97.2)
PSA (ng/mL), mean±SD 1.26±1.13 1.28±1.01 1.17±0.82 1.34±1.44
PSA, prostate specific agent; SD, standard deviation. 
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age PSA decrement at the third month of the operation in 55 
patients with BOOI ≥ 40 and 24 patients with BOOI < 40 were 
78.09 ± 4.96 and 8.09 ± 5.85 ng/mL respectively (P= 0.997) 
(Table 3).
 The biopsy results of resected tissue by TURP were as fol-
lowed; 91 patients with nodular hyperplasia, 75 patients with 
chronic inflammation, eight patients with low-grade prostatic 
intraepithelial neoplasia (PIN) and 12 patients with adeno-
carcinoma. There was no significant difference in the preop-
erative PSA level, PSAD and the level of the PSA decrement 
at 3rd months of TURP between patients with different histo-
logic characteristics. At third months after TURP, the IPSS de-
creased from 19.2 ± 8.0 to 7.5 ± 5.5 (P= 0.006) and the quality 
of life decreased from 4.2 ± 1.2 to 1.5 ± 1.1 (P= 0.04). The Qmax 
increased from 8.7 ± 4.0 to 15.6 ± 6.6 mL/sec (P= 0.04) and the 
PVR decreased 131.8 ± 201.0 to 30.0 ± 44.8 mL (P= 0.001). 
 Among 12 patients with prostate cancer, four patients with 
Gleason score < 7 were treated with active surveillance and 
four patients with Gleason score≥7 were conducted hormonal 
therapy. Each of two patients with Gleason scores 6 and 7 
requested surgical treatment and the biopsy result of these 
patients showed remnant prostate cancer less than 3% of 
specimen without overgraded cancer.
 
DISCUSSION
In BPH patients who were suspected as prostate cancer despite 
previous negative prostate biopsy, TURP normalized dramati-
cally and maintained the PSA level for an extended period of 
time. TURP also could be helpful for diagnosis of clinically 
significant prostate cancer in transition zone, which was un-
detected in previous biopsy. 
 Approximately 20%–30% of prostate cancers are found in 
the transition zone or anterior portion of the prostate where 
it is difficult to obtain a TRUS biopsy [11]. Presently, magnetic 
resonance imaging (MRI) is the best modality to localize, 
monitor, and stage tumors. Studies have shown modern MRI 
techniques, including dynamic contrast-enhanced MRI, 3T-
diffusion-weighted imaging and functional MRI, to increase 
the rate of tumors detected [12-14]. Other reports have ex-
amined prostates for suspicious lesions by MRI or MRI com-
bined with a real-time TRUS-guided prostate biopsy [15,16]. 
Despite these advance, clinicians still have challenging issues 
in determining the additional prostate biopsies or the direc-
tion of future treatment in cases where the serum PSA level 
remains elevated. 
 TURP is another method that is useful in the detection of 
prostate cancer [17-20]. Yates et al. [19] report that the can-
cer detection rate in previous biopsy-negative patient was 
higher in receiving TURP and saturation prostate biopsy (SBx, 
38.9%) than in receiving SBx alone (27.1%). Ploussard et al. 
[20] describe similar results, namely, a 28.5% increase in the 
cancer detection rate in 113 patients that underwent TURP 
plus 21-core biopsies compared to 21-core biopsies alone. In 
this study, 6.5% of previous biopsy-negative patients (12/186) 
were diagnosed with prostate cancer after TURP, and six of 
these patients had a Gleason score of ≥ 7. Taken collectively, 
these results indicate that TURP is invaluable in the detec-
tion of prostate cancer and building of treatment plan such as 
active surveillance for low grade cancer and surgical or hor-
monal therapy for aggressive cancer. 
 TURP can reduce PSA level in patient with BPH. Plous-
sard et al. [20] report that the serum PSA level normalized in 
57% of patients after TURP. In addition, the average preopera-
tive PSA level in patients without prostate cancer decreased 
from 10.4 to 4.2 ng/mL 1 month after TURP, and this level was 
maintained at 1 year after the procedure. Furthermore, van 
Renterghem et al. [21] report the cancer detection rate and 
the long-term monitoring of the PSA after performing the 
TURP in 82 consecutive patients with more than 4 ng/mL of 
the PSA and the negative previous prostate biopsy; the aver-
age PSA level of the 74 cancer free patents decreased from 8.2 
to 0.9 ng/mL 1 year after TURP. Ninety-seven point two per-
centage of the patients (35/36) showed the permanent nor-
malized PSA ( < 4 ng/mL). In this study, the PSA level normal-
ized in 95.5% of patients (106/112) at 3 months after TRUP 
(mean PSA, 1.26 ± 1.13 ng/mL), and this level was maintained 
in 97.2% of patients (35/36) 3 years after TRUP. 
 In study by Ploussard et al. [20], additional 21-core pros-
tate biopsy was performed to the patients who did not show 
normalization of the PSA level after TURP. Six of the 30 pa-
tients (20%) were diagnosed as prostate cancer. In this study, 
we performed additional TRUS biopsy to the patients who 
showed increased PSA level after TURP. The PSA level in-
creased by >1 ng/mL in three patients during 3 years follow-
up period; one of these three patients did not show PSA nor-
malization for entire follow-up period and had one atypical 
small acinar proliferation in three consecutive prostate biop-
sies. Another two patients did not have the evidence of pros-
tate cancer. The PSA level of another patient, who had PSA 
normalization after TURP, showed dramatically increased 
again to 8.12 ng/mL at 7 years after TRUP. Following a TURS 
biopsy, robot assisted laparoscopic radical prostatectomy was 
performed. These studies support that the TURP could nor-
malize and maintained the PSA level persistently unless new 
prostate cancer newly developed. This could help prostate 
Cho, et al. TURP in patients with BPH and elevated PSA level
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cancer screening with PSA level easily performed and reduce 
the anxiety of prostate cancer for clinician and patients if PSA 
is not increased again. 
 The PSA level can increase due to many causes [1]. The PSA 
level is directly linked with bladder outlet obstruction (BOO), 
prostate volume, and BPH-related events. Laniado et al. [22] 
show an association between a high PSA level and urodynam-
ically-defined BOO in patients with a PSA level < 10 ng/mL 
and LUTS. Van Renterghem et al. [21] also show a correlation 
between the urodynamically defined BOO and the PSA level 
before surgery, and they suggest that this is the reason for the 
increase in the PSA level in patients with a negative prostate 
biopsy. However, in this study, there was no significant differ-
ence of PSA and PSAD between the urodynamic obstructed 
group (BOOI ≥ 40) and the equivocal or unobstructed group 
(BOOI < 40). We thought that if the degree of BOO is strong 
cause of elevated PSA, the extent of PSA decrement after 
resolving of BOO could be correlated with PSA decrement. 
The residual prostatic weight ratio was between both groups 
but there is no significant difference; therefore, we could not 
prove the relationships between the urodynamically defined 
BOO and the elevated PSA.
 Chronic inflammation without prostate cancer is one of the 
most frequent causes of an elevated PSA level. Kandirali et al. 
[23] report that the extent and aggressiveness of inflamma-
tion correlated positively with the serum PSA level and PSAD. 
Serretta et al. [24] show that the PSA level normalized in 59.6% 
of patients after using antibiotics for three weeks. When the 
PSA remained high even after the antibiotics treatment, there 
was a two-fold increase in the prostate cancer detection. In 
this study, 40.3% of patients (75/186) presented with chronic 
inflammation. However, there were no significant differences 
in the PSA level and PSAD in patients with chronic prostatitis 
or low-grade PIN, nodular hyperplasia and even adenocarci-
noma. Under the hypothesis that reduction of prostate tissue 
presented an inflammation or abnormal cell could influence 
the extent of PSA decrement, we compared extent of the PSA 
decrement at 3 months after TURP between the patients with 
nodular hyperplasia and with chronic prostatitis but there was 
no significant difference. In the presence of low-grade PIN or 
prostate cancer, there was a little more decrease in the PSA 
level 3 months after TURP but was not statistically significant. 
We did not find the correlation between PSA and histologic 
feature of prostate. 
 While we did not show a correlation between the BOO lev-
el or histological features and PSA, we thought these factors 
are strong influencing factor of elevated PSA level. Prostate 
volume is also one of the solid reasons for elevated PSA level 
[25,26]. The prostate volume in the aforementioned several 
studies was 30–50 mL. But the average prostate volume of the 
patients enrolled in this study was 71.5 mL which is almost 
double the number of the average prostate volume (36.9 mL) 
of Korean male patients with LUTS [27]. Thus, a large prostate 
volume in present study may mask the effect of BOO and 
histologic feature on the increase of PSA level. In the clini-
cal practice, elevated PSA despite negative prostate biopsy 
gives the doctor many difficulties to determine the direction 
of treatment. Furthermore, in patients with larger prostate, 
clinicians have more ambiguity for evaluating the reason of 
elevated PSA and there is a greater chance of missing the can-
cer by a TRUS biopsy compared to the patients with smaller 
prostate. Therefore, TURP followed by careful monitoring of 
the PSA level is the good method to detect undiagnosed pros-
tate cancer and easily screen the newly developed prostate 
cancer without the anxiety for the elevated PSA. 
 There are several limitations in this study. This was a retro-
spective study, and data on the PSA level are missing in many 
cases after 1 year of TURP. But dramatic deceasing of PSA 
level was confirmative with large number of followed up pa-
tients at 3 months after TURP and this trend was persistently 
maintained up to 3 years. Additional prospective study with 
large number of patient is necessary to reveal definite conclu-
sion and that will be helpful for further evaluation of the role 
of PSAV and PSAD for predicting newly occurrence of pros-
tate cancer during follow up after TURP.
 In conclusion, TURP can improve prostate cancer detec-
tion and effectively normalize the serum PSA level in long-
term follow-up. It is thought that TURP makes the prostate 
screening using PSA level easier in patients with an elevated 
PSA level and a negative previous biopsy. We recommend 
that monitoring of PSA value and a TRUS biopsy on patients 
with an increased serum PSA level after TRUP. Further pro-
spective study of a larger population and longer follow-up are 
necessary.
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